iMOS® improves gut microbiota and function, and helps to relieve the symptoms associated with intestinal inflammations (constipation & diarrhea)
Intestinal inflammations (IBS, IBD, etc.) are often associated with the destruction of intestinal structural integrity. iMOS® can improve gut integrity by increasing the length of the small intestinal villus, thickening the wall of the small intestine.
iMOS® improves diabetes (type II) control
Type II diabetes is associated with obesity, and patients are more likely to develop IR. IR is a condition in which cells no longer respond to the hormone and no longer absorb glucose. Experiments show that iMOS® is effective in reducing plasma glucose (FBG), hemoglobin A1C (HbA1c), and HOMA-IR, and a synergistic effect is observed when combining iMOS® and MF (the most widely used first-line drug for the treatment of type II diabetes). It also increases the abundance of Akkermansia muciniphila and Bifidobacterium pseudolongum, which is positively associated with the prevention and treatment of obesity and diabetes (type II) (Fig.1).
Fig.1 iMOS® effectively improves the indicators of type II diabetes and also regulates the flora structure of the intestines.
Ref: Prebiotic mannan-oligosaccharides augment the hypoglycemic effects of MF in correlation with modulating gut microbiota. Zheng et al. J. Agric. Food Chem. 2018 Apr. 27